ARTICLE INSIGHTS! Thank you @drphil_urology for your insights into, "Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy." 🔗 Read more: https://t.co/MVPiNrNvAK

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

Review @ImmunityCP @calico More TOR: The expanding role of mTOR in regulating immune responses https://t.co/eGfWuPBjSb

Great job pgy5 @aghasemzadeh1 on your poster #AUA25! @WiscUroOnc @UroOnc @ejasonabel

From the March issue: Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer. https://t.co/DvhrUrSE4O By @LChesNerd, @felixfengmd, @Moran_Lab, and colleagues @UCSFCancer @OHSUKnight

NIAGARA’s surgical safety results #EAU25 with Jim Catto. Results show the addition of duvalumab to neoadjuvant platinum chemotherapy did not increase surgical complications or cystectomy rates.

Thrilled to be headed to @UrologyMSK for @UroOnc fellowship! @arihakimi Couldn’t have done it without the support of all my mentors along the way @ejasonabel @d_shapiro1 @Uro_Rich @DavidJarrardMD @mchlrisk @tudor_borza

Great job to our @WiscUroOnc @wiscurology students, residents, and fellow presenting their research at Wisconsin urological society meeting. No one moderates better than #MikeRisk

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Online Now: The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions https://t.co/WpIZ19zHGo

Platinum-based chemotherapy is the standard of care for previously untreated unresectable or metastatic urothelial carcinoma, w/ cisplatin-based chemotherapy preferred for eligible pts. Full CheckMate 901 trial Research Summary by @MichvdHeijden et al.:

Fascinating discovery by @Annaglobig! Exhausted CD8 T cells talk to sympathetic nerves in tissues & tumors. Tex cells express ADRB1 and localize near sympathetic nerves, listening to stress hormone noradrenaline. This promotes their dysfunction.

Results from our Ph2 study using Durva in BCG Unresponsive CIS is online @CCR_AACR 👉2/17 CR at 6mo 👉1/17 Gr 3 hepatotoxicity 👉1/17 PD-L1 high pre-treatment https://t.co/K7GcqPt6fP #JingsongZhang @WadeJSexton9 @SpiessPhilippe @sgilbert1973 @JulioPowSangMD #JRCG @MoffittGUOnc

Online Now: Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals https://t.co/T7rmF4m8b7 @d_shapiro1 @LoganZemp @virajmaster @WadeJSexton9 @aghasemzadeh1 @b_schmeusser @FDavaro @SurenaMatinMD @SpiessPhilippe @ejasonabel

A new candidate vaccine against NMIBC in a multi institutional study in close collaboration with @tbivala1 Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against…

Online today @CellCellPress. By identifying and classifying recurrent immune features, we discovered 12 unique dominant tumor Archetypes that span cancer types. This immune-based classification provides a framework toward understanding tumor immunity to guide immunotherapies 1/n.

In pts with ccRCC, high AXL expression levels in tumour cells is associated high PD-L1 expression, especially in VHL mutated cells, and with lower ORRs and a trend to shorter PFS following second-line anti-PD-1 treatment: https://t.co/LU0PJnwDbr #kcsm #ImmunoOnc

How does one define exhaustion? As many have shown with ATACseq (@EJohnWherry, @nickhaining, etc.), exhausted T cells are a lineage: posessing a relatively fixed chromatin landscape with unique accessible regions that define them the way Th1 vs Th2 are defined.

Couldn’t be prouder to have worked with the Drake and Califano teams at @columbiacancer on this project, now out today in @CellCellPress. Special shout-out to first authors Aleks,@ChowdhuryNivi, and @DrScottHaake for their hard work!